Register For Our Mailing List

Register to receive our free weekly newsletter including editorials.

Home / 186

The market loves growth stocks – until it doesn’t

In light of the recent misfortunes suffered by high-profile ASX growth stocks (Bellamy’s, Estia Health, and iSentia Group to name a few), it’s worthwhile seeing if there are any obvious lessons investors can take into 2017.

Growth stocks by their nature tell a story that provides some justification of their future earnings potential. These stocks can dazzle as their futures unfold, but it’s important to remember the other side of the trade when things don’t go as planned.

High profile growth stocks volatile

Firstly, from a risk perspective, investors benefit from knowing how a growth stock will compare with the wider market. Beta is the measure of the volatility of a security versus the market. It can provide an indication of how volatile or ‘wild’ the ride might be, from both positive and negative sides. For example, if growth Company A has a market beta of 1.5 it is likely to be 50% more volatile than the market. That is, if the market goes up 1% then Company A should rise 1.5% and if the market falls by 1% Company A should fall by 1.5%.

Secondly, the cliché ‘up the stairs down the elevator’ is particularly relevant when looking at growth stocks. Put simply, a company is more likely to go from overvalued to undervalued far more quickly than from undervalued to overvalued. Growth stocks are either undervalued or overvalued but rarely fairly valued. We know the higher the price the higher the risk, yet our FOMO (fear of missing out) may cause us to jump into a growth stock, chasing and in fact promoting the ‘paper profits’ seen by the earlier investors.

On the flip side, our apprehension may cause us to sell out at a large and sudden discount even though the risks of the business are provided at a large discount.

Market has a short memory

If you ask the question (assuming business fundamentals remain), that if I was happy to buy stock at a 30% discounted price on the way up, shouldn’t I be considering buying it now?

The market tends to have a short memory and is always willing to be swept away by the next big growth stock. If we take a look back to calendar year 2015, the top 10 performers in the All Ordinaries Index produced an average return of approximately 400% (if you exclude resource companies, the top 10 performers returned an average of approximately 275%). Leading the charge were the market darlings, Bellamy’s and Blackmores, which had P/Es of 140 and 80 respectively during that time. The market is forward looking to a current P/E on a growth stock so it will invariably look high, but these figures also provide a sense of relativity to the general market P/E range of 15-17.

If we look at those same performing stocks in calendar year 2016 (so far), the return of the non-resource top 10 market darlings from 2015 is -18%, excluding one which has gone into liquidation. Of those which have produced negative returns, the average is -35%. A company reinvesting for growth often means you don’t have a dividend yield to soften the loss, and an investor that arrives late to the party can end up with negative returns quickly.

Here are four lessons to keep in mind before investing in growth stocks:

  • have a price level of where you think the stock is either undervalued or overvalued and write it down so you don’t forget
  • don’t ignore a company’s beta - the higher the beta, the higher the risk of a larger pullback
  • chasing someone else’s paper profit is not a sound investment decision
  • if you’re caught up in a large correction, take your time to weigh the options in the context of undervalued vs overvalued. Has the bubble burst or is this an opportunity to buy at a price you could only have dreamed of a few days ago?

 

Robert Miller is a Portfolio Manager at NAOS Asset Management. NAOS runs two LICs, ASX:NCC and ASX:NAC. This article is general information and does not consider the circumstances or investment needs of any individual.

 

RELATED ARTICLES

Six ratios show the market is off the charts

4 lessons from Marks on protecting capital

Insider sales can be a powerful warning

banner

Most viewed in recent weeks

10 little-known pension traps prove the value of advice

Most people entering retirement do not see a financial adviser, mainly due to cost. It's a major problem because there are small mistakes a retiree can make which are expensive and avoidable if a few tips were known.

Check eligibility for the Commonwealth Seniors Health Card

Eligibility for the Commonwealth Seniors Health Card has no asset test and a relatively high income test. It's worth checking eligibility and the benefits of qualifying to save on the cost of medications.

Hamish Douglass on why the movie hasn’t ended yet

The focus is on Magellan for its investment performance and departure of the CEO, but Douglass says the pandemic, inflation, rising rates and Middle East tensions have not played out. Vindication is always long term.

Start the year right with the 2022 Retiree Checklist

This is our annual checklist of what retirees need to be aware of in 2022. It is a long list of 25 items and not everything will apply to your situation. Run your eye over the benefits and entitlements.

At 98-years-old, Charlie Munger still delivers the one-liners

The Warren Buffett/Charlie Munger partnership is the stuff of legends, but even Charlie admits it is coming to an end ("I'm nearly dead"). He is one of the few people in investing prepared to say what he thinks.

Should I pay off the mortgage or top up my superannuation?

Depending on personal circumstances, it may be time to rethink the bias to paying down housing debt over wealth accumulation in super. Do the sums and ask these four questions to plan for your future.

Latest Updates

Investment strategies

Three ways index investing masks extra risk

There are thousands of different indexes, and they are not all diversified and broadly-based. Watch for concentration risk in sectors and companies, and know the underlying assets in case liquidity is needed.

Investment strategies

Will 2022 be the year for quality companies?

It is easy to feel like an investing genius over the last 10 years, with most asset classes making wonderful gains. But if there's a setback, companies like Reece, ARB, Cochlear, REA Group and CSL will recover best.

Shares

2022 outlook: buy a raincoat but don't put it on yet

In the 11th year of a bull market, near the end of the cycle, some type of correction is likely. Underneath is solid, healthy and underpinned by strong earnings growth, but there's less room for mistakes. 

Gold

Time to give up on gold?

In 2021, the gold price failed to sustain its strong rise since 2018, although it recovered after early losses. But where does gold sit in a world of inlfation, rising rates and a competitor like Bitcoin?

Investment strategies

Global leaders reveal surprises of 2021, challenges for 2022

In a sentence or two, global experts across many fields are asked to summarise the biggest surprise of 2021, and enduring challenges into 2022. It's a short and sweet view of the changes we are all facing.

Shares

2021 was a standout year for stockmarket listings

In 2021, sharemarket gains supported record levels of capital raisings and IPOs in Australia. The range of deals listed here shows the maturity of the local market in providing equity capital.  

Economy

Let 'er rip: how high can debt-to-GDP ratios soar?

Governments and investors have been complacent, even encouraged, the build up of debt, but somewhere, a ceiling exists. Are we near yet? Trouble is brewing, especially in the eurozone and emerging countries.

Sponsors

Alliances

© 2022 Morningstar, Inc. All rights reserved.

Disclaimer
The data, research and opinions provided here are for information purposes; are not an offer to buy or sell a security; and are not warranted to be correct, complete or accurate. Morningstar, its affiliates, and third-party content providers are not responsible for any investment decisions, damages or losses resulting from, or related to, the data and analyses or their use. Any general advice or ‘regulated financial advice’ under New Zealand law has been prepared by Morningstar Australasia Pty Ltd (ABN: 95 090 665 544, AFSL: 240892) and/or Morningstar Research Ltd, subsidiaries of Morningstar, Inc, without reference to your objectives, financial situation or needs. For more information refer to our Financial Services Guide (AU) and Financial Advice Provider Disclosure Statement (NZ). You should consider the advice in light of these matters and if applicable, the relevant Product Disclosure Statement before making any decision to invest. Past performance does not necessarily indicate a financial product’s future performance. To obtain advice tailored to your situation, contact a professional financial adviser. Articles are current as at date of publication.
This website contains information and opinions provided by third parties. Inclusion of this information does not necessarily represent Morningstar’s positions, strategies or opinions and should not be considered an endorsement by Morningstar.

Website Development by Master Publisher.